Hoth Therapeutics (HOTH) announced its engagement with ICON Clinical Research to expand its Phase II Clinical Trial for cancer patients suffering from skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors. Additional regulatory approval for the Phase II clinical trial is expected from potentially three EU countries in the upcoming months. The EU approval is part of the company’s international clinical development strategy for HT-001. The trial is currently enrolling patients in the U.S. This Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics signs VA research deal to advance GDNF in obesity, fatty liver
- Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
- Silo Pharma enters into letter of intent to form 50:50 joint venture with Hoth
- Hoth and Silo form strategic joint venture to develop obesity treatment
- Hoth Therapeutics Advances HT-001 for Cancer Treatment